AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14671698 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced duplex ultrasound (Definity, infused at 2 to 4 mL/min)
Number of subjects: 22
Study 14671698 — intervention group
Group type: COMPARATOR
Intervention: Standard duplex ultrasound
Number of subjects: 22
Study 14671698 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced duplex ultrasound
Number of subjects: 22
Study 11007149 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 291
Study 11007149 — intervention group
Group type: COMPARATOR
Intervention: Standard advice
Number of subjects: 291
Study 9179187 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen ablation therapy (AAT)
Number of subjects: 258
Study 9179187 — intervention group
Group type: COMPARATOR
Intervention: No androgen ablation therapy (no AAT)
Number of subjects: 258
Study 1350140 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon alpha 2a plus cryotherapy
Number of subjects: 0
Study 1350140 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 0
Study 2859970 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline, 0.5 mg intravenously
Number of subjects: 12
Study 2859970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2859970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol, 1.0 and 4.0 mg intravenously
Number of subjects: 12
Study 31821915 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-quadrant osteoplastic decompressive craniotomy (FoQOsD)
Number of subjects: 115
Study 31821915 — intervention group
Group type: COMPARATOR
Intervention: Conventional decompressive craniectomy (DC)
Number of subjects: 115
Study 31821915 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intraventricular hemorrhage and subarachnoid hemorrhage
Number of subjects: 115
Study 31821915 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposite side contusions
Number of subjects: 115
Study 31821915 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisocoria
Number of subjects: 115
Study 30791502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary feedback text messaging intervention
Number of subjects: 143
Study 28535438 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg
Number of subjects: 30
Study 28535438 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 90 mg
Number of subjects: 30
Study 28535438 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban 60 mg in sodium citrate tubes
Number of subjects: 30
Study 28535438 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban 90 mg in sodium citrate tubes
Number of subjects: 30
Study 25732165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 200 mg/m2 continuous IV infusion once per day on days 1 to 7 plus amonafide 600 mg/m2 IV over 4 hours on days 1 to 5 (A + C arm)
Number of subjects: 433
Study 25732165 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine 200 mg/m2 continuous IV infusion once per day on days 1 to 7 plus daunorubicin 45 mg/m2 IV over 30 minutes once per day on days 1 to 3 (D + C arm)
Number of subjects: 433
Study 23800209 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperatively planned surgery using VSP software
Number of subjects: 5
Study 23800209 — intervention group
Group type: COMPARATOR
Intervention: Free-hand surgery without VSP software
Number of subjects: 5
Study 23800209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (VSP and free-hand)
Number of subjects: 5
Study 21790765 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butylscopolammonium bromide (NBB) 0.3 mg/kg bwt i.v.
Number of subjects: 6
Study 21790765 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine 0.25 mg/kg bwt i.v.
Number of subjects: 6
Study 21790765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NBB (0.3 mg/kg bwt) and xylazine (0.25 mg/kg bwt) i.v.
Number of subjects: 6
Study 19561254 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided percutaneous treatment
Number of subjects: 287
Study 16756418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude voucher group
Number of subjects: 60
Study 16756418 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication contingency group
Number of subjects: 60
Study 16756418 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 60
Study 15472588 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein
Number of subjects: 100
Study 15472588 — intervention group
Group type: COMPARATOR
Intervention: Ligation alone
Number of subjects: 100
Study 11199739 — intervention group
Group type: EXPERIMENTAL
Intervention: Drying with one paper point
Number of subjects: 80
Study 11199739 — intervention group
Group type: EXPERIMENTAL
Intervention: Drying with four paper points
Number of subjects: 80
Study 11199739 — intervention group
Group type: EXPERIMENTAL
Intervention: Drying with four paper points followed by a gentle burst of warm air
Number of subjects: 80
Study 11199739 — intervention group
Group type: EXPERIMENTAL
Intervention: Drying with four paper points followed by an internal 200 degrees C heat probe
Number of subjects: 80
Study 11199739 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealer
Number of subjects: 80
Study 11199739 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide-eugenol sealer
Number of subjects: 80
Study 9255203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral malaria survivors
Number of subjects: 624
Study 8222516 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (0.015 to 0.075 microgram min‐1 kg‐1) during euhydration
Number of subjects: 15
Study 8222516 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (0.015 to 0.075 microgram min‐1 kg‐1) during overhydration
Number of subjects: 15
Study 8222516 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion
Number of subjects: 15
Study 2939869 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 16 mg daily
Number of subjects: 36
Study 2939869 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 36
Study 2939869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30944149 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSAFE physiotherapy programme (individually tailored, progressive home-based fall avoidance strategy training with balance and strengthening exercises)
Number of subjects: 474
Study 30944149 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care, DVD about Parkinson's, single advice session)
Number of subjects: 474
Study 30944149 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSAFE physiotherapy programme
Number of subjects: 474
Study 30944149 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 474
Study 28252452 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 0
Study 28252452 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate (PP)
Number of subjects: 0
Study 26255249 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) monotherapy
Number of subjects: 30
Study 24021562 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with sensory discrimination training
Number of subjects: 25
Study 24021562 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture without sensory discrimination training
Number of subjects: 25
Study 21497708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (200 mL twice daily for 2 weeks)
Number of subjects: 16
Study 21497708 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 16
Study 19048695 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE (ifosfamide, carboplatinum, etoposide)
Number of subjects: 73
Study 19048695 — intervention group
Group type: COMPARATOR
Intervention: IMVP (ifosfamide, methotrexate, etoposide)
Number of subjects: 73
Study 17133780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nourkrin (active preparation)
Number of subjects: 55
Study 12504702 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiquadrant cortical‐cleaving hydrodissection (HY)
Number of subjects: 59
Study 12504702 — intervention group
Group type: COMPARATOR
Intervention: No hydrodissection (HN)
Number of subjects: 59
Study 10393602 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Positive Pressure Ventilation (IPPV)
Number of subjects: 284
Study 10393602 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Ventilation (HFV)
Number of subjects: 284
Study 8753981 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-sclera technique
Number of subjects: 55
Study 8753981 — intervention group
Group type: COMPARATOR
Intervention: Free conjunctiva-limbus transplant
Number of subjects: 55
Study 1677229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 micrograms/kg
Number of subjects: 20
Study 1677229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 micrograms/kg
Number of subjects: 20
Study 1677229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.5 micrograms/kg
Number of subjects: 20
Study 1677229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 20
Study 6841074 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic retinoid (Ro 10‐9359)
Number of subjects: 4
Study 6841074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 6841074 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 4
Study 29866011 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal 300 mg twice daily or 600 mg once daily
Number of subjects: 1119
Study 29866011 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 1119
Study 29866011 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal
Number of subjects: 1119
Study 29866011 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1119
Study 29424731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac shock wave therapy (CSWT)
Number of subjects: 72
Study 29424731 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 72
Study 26768165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 121
Study 26768165 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 121
Study 25010443 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Number of subjects: 70
Study 25010443 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 70
Study 21691847 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (≥ 65 years)
Number of subjects: 57
Study 21691847 — intervention group
Group type: COMPARATOR
Intervention: Younger patients (< 65 years)
Number of subjects: 57
Study 20199764 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV-23)
Number of subjects: 0
Study 20199764 — intervention group
Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (PCV-7)
Number of subjects: 0
Study 18043484 — intervention group
Group type: EXPERIMENTAL
Intervention: 800‐mg oral dose of EGCG administered as Polyphenon E under fasting conditions
Number of subjects: 10
Study 18043484 — intervention group
Group type: EXPERIMENTAL
Intervention: 800‐mg oral dose of EGCG administered as Polyphenon E under fed conditions
Number of subjects: 10
Study 18043484 — intervention group
Group type: EXPERIMENTAL
Intervention: OSS‐3 sampling strategy
Number of subjects: 10
Study 18043484 — intervention group
Group type: EXPERIMENTAL
Intervention: OSS‐2 sampling strategy
Number of subjects: 10
Study 16251628 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation of breast‐feeding mothers with 60 mg retinol equivalent (RE) vitamin A within 4 wk of delivery
Number of subjects: 1085
Study 16251628 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI‐linked supplementation of infants with 7.5 mg RE vitamin A at 6, 10, and 14 wk
Number of subjects: 1085
Study 16251628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mother and child supplementations
Number of subjects: 1085
Study 16251628 — intervention group
Group type: COMPARATOR
Intervention: Placebo for mother and child
Number of subjects: 1085
Study 12093601 — intervention group
Group type: EXPERIMENTAL
Intervention: Brahmi (Bacopa monnieri)
Number of subjects: 76
Study 10342896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (current smokers)
Number of subjects: 507
Study 10342896 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat intake
Number of subjects: 507
Study 10342896 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of lung cancer
Number of subjects: 507
Study 10342896 — intervention group
Group type: COMPARATOR
Intervention: Residential patterns, air quality, occupation
Number of subjects: 507
Study 7500240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler at full power
Number of subjects: 17
Study 7500240 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaler at half power
Number of subjects: 17
Study 1758201 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline 0.5 mg inhaled through a cone spacer with positive expiratory pressure (+PEP)
Number of subjects: 0
Study 1758201 — intervention group
Group type: COMPARATOR
Intervention: terbutaline 0.5 mg inhaled through a cone spacer without positive expiratory pressure (‐PEP)
Number of subjects: 0
Study 7093597 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amitriptyline (75-225 mg/day)
Number of subjects: 68
Study 7093597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular flupenthixol decanoate (10-30 mg every 14 days)
Number of subjects: 68
Study 31526640 — intervention group
Group type: EXPERIMENTAL
Intervention: New domestic dacron patch
Number of subjects: 48
Study 31526640 — intervention group
Group type: COMPARATOR
Intervention: Imported cardiac polyester patch
Number of subjects: 48
Study 30762726 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual bronchoscopic navigation combined with endobronchial ultrasound (VBN+EBUS)
Number of subjects: 115
Study 30762726 — intervention group
Group type: COMPARATOR
Intervention: Endobronchial ultrasound (EBUS)
Number of subjects: 115
Study 28838955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 200 mg/d
Number of subjects: 172
Study 28838955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled bosutinib (200 mg/d and 400 mg/d)
Number of subjects: 172
Study 28838955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 23782554 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-free soy-maize-sorghum-based RUTF (SMS-RUTF)
Number of subjects: 1927
Study 23782554 — intervention group
Group type: COMPARATOR
Intervention: Standard ready-to-use therapeutic food with 25% milk (P-RUTF)
Number of subjects: 1927
Study 24830824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (DEX implant)
Number of subjects: 427
Study 24830824 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 427
Study 22462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 257
Study 22462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 257
Study 22462654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence of tamoxifen and letrozole
Number of subjects: 257
Study 22462654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-2 normal patients subset of Danish cohort
Number of subjects: 257
Study 19736426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide (DCP+C)
Number of subjects: 28
Study 19736426 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide pulse and daily oral prednisolone (CP+P)
Number of subjects: 28
Study 17307419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary beta-irradiation (VBT)
Number of subjects: 61
Study 17307419 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (control group)
Number of subjects: 61
Study 15310844 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with genetically engineered allergen derivatives
Number of subjects: 124
Study 10923750 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine (300 mg daily, with fallback to 150 mg if necessary)
Number of subjects: 121
Study 10923750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 9365037 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step polymerase chain reaction assay
Number of subjects: 35
Study 9365037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested polymerase chain reaction assay
Number of subjects: 35
Study 9365037 — intervention group
Group type: COMPARATOR
Intervention: Polymerase chain reaction assay
Number of subjects: 35
Study 1590226 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 200 mg/day
Number of subjects: 212
Study 1590226 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study 3897808 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (2 atmospheres absolute for 20 sessions of 90 minutes, over a period of one month)
Number of subjects: 41
Study 3897808 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas mixture
Number of subjects: 41
Study 3371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-complex
Number of subjects: 31
Study 3371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 31
Study 3371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 31
Study 3371295 — intervention group
Group type: COMPARATOR
Intervention: EFA nutriture (compared with controls)
Number of subjects: 31
Study 3371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E levels in patients treated with safflower oil
Number of subjects: 31
Study 3371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Other fatty acids levels
Number of subjects: 31
Study 3371295 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical features and severity
Number of subjects: 31
Study 30706798 — intervention group
Group type: COMPARATOR
Intervention: Younger adults (18-49 years) during M1 task
Number of subjects: 54
Study 30706798 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (>50 years) during M1 task
Number of subjects: 54
Study 30706798 — intervention group
Group type: COMPARATOR
Intervention: Younger adults (18-49 years) during V1 task
Number of subjects: 54
Study 30706798 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (>50 years) during V1 task
Number of subjects: 54
Study 30706798 — intervention group
Group type: COMPARATOR
Intervention: Younger adults (18-49 years) during V2 task
Number of subjects: 54
Study 30706798 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (>50 years) during V2 task
Number of subjects: 54
Study 29023213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 854
Study 29023213 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 854
Study 26166555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein hypocaloric diet (Diet HP)
Number of subjects: 331
Study 26166555 — intervention group
Group type: COMPARATOR
Intervention: Standard hypocaloric diet (Diet S)
Number of subjects: 331
Study 23190599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 135)
Number of subjects: 276
Study 23190599 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (n = 141)
Number of subjects: 276
Study 21396130 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 21396130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18479589 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 282
Study 18479589 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 6.25 mg + Atenolol 25 mg
Number of subjects: 282
Study 18479589 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg + Amlodipine 2.5 mg
Number of subjects: 282
Study 16547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 100
Study 16547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic epinephrine
Number of subjects: 100
Study 16547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 100
Study 12928310 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic adaptive servoventilation for 1 month
Number of subjects: 30
Study 12928310 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic adaptive servoventilation for 1 month (Control)
Number of subjects: 30
Study 11009045 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (500 mg, 250 mg, 250 mg over 12 h) followed by co-artemether (6 x 4 tablets over 60 h)
Number of subjects: 14
Study 11009045 — intervention group
Group type: COMPARATOR
Intervention: Co-artemether alone
Number of subjects: 14
Study 11009045 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine alone
Number of subjects: 14
Study 8884415 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training program (48 sessions, 3 sessions/week)
Number of subjects: 30
Study 8884415 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary lifestyle)
Number of subjects: 30
Study 8884415 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 30
Study 1405960 — intervention group
Group type: EXPERIMENTAL
Intervention: Canal preparation with Betadine and alcohol
Number of subjects: 130
Study 1405960 — intervention group
Group type: COMPARATOR
Intervention: Nonprepared (control)
Number of subjects: 130
Study 4057312 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg IM
Number of subjects: 20
Study 4057312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29409922 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) infiltration
Number of subjects: 50
Study 29409922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infiltration
Number of subjects: 50
Study 27940715 — intervention group
Group type: COMPARATOR
Intervention: Control (visual and clinical assessment for SB)
Number of subjects: 430